Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Success for Merck Serono's oral cladribine in pivotal Phase III MS trial

This article was originally published in Scrip

Executive Summary

Merck KGaA's oral formulation of cladribine has met its primary endpoint of a reduction in the relapse rate in patients with the most common form of multiple sclerosis in its first, large two-year Phase III trial. The company plans to file the drug for this use in mid-2009 in both Europe and the US.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel